Solbec anti-cancer compound gets good news from FDA

Solbec Pharmaceuticals Limited has announced its lead anti-cancer compound Coramsine has received orphan drug designation from the US Food and Drug Administration. The compound is used for the treatment of metastatic renal cell carcinoma. Solbec's strategy is to market Coramsine within 3 - 5 years.


(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

BNIQ sponsored byECU School of Business and Law


6th-Australian Institute of Management WA20,000
7th-Murdoch University16,584
8th-South Regional TAFE10,549
9th-Central Regional TAFE9,064
10th-The University of Notre Dame Australia6,708
46 tertiary education & training providers ranked by total number of students in WA

Number of Employees

BNiQ Disclaimer